Skip to main content

Severe Acute Respiratory Syndrome

Respiratory
4
Pipeline Programs
8
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
250%
Vaccine
125%
Monoclonal Antibody
125%
+ 5 programs with unclassified modality

Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.

$39.4B marketMature→ Stable30 products15 companies

Key Trends

  • Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
  • Major patent expirations 2026-2031 creating $7.8B revenue cliff
  • High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity

Career Verdict

Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISGrowing
$18.3B
Bristol Myers Squibb·Launch15.0yr
#3TRELEGY ELLIPTADeclining
$4.5B
GSK·Peak4.9yr
#4CREONDeclining
$1.5B
AbbVie·Approaching LOE
#5BREO ELLIPTADeclining
$1.4B
GSK·Peak4.9yr

Drug Class Breakdown

FXa Inhibitors
$18.3B(46%)

dominant market driver

Unknown/Undisclosed Mechanism
$9.7B(25%)

fragmented portfolio

GLP-1 Receptor Agonists
$7.4B(19%)

rapidly expanding

Pancreatic Enzymes
$1.5B(4%)

legacy product

Corticosteroid/LABA Combinations
$796M(2%)

patent cliff approaching

Long-Acting Muscarinic Antagonists
$456M(1%)

mature maintenance therapy

Career Outlook

Stable

Respiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.

Breaking In

New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.

For Experienced Professionals

Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.

In-Demand Skills

Commercial execution and territory managementMedical Affairs/Key Opinion Leader engagementRegulatory affairs and lifecycle managementInhalation device expertise and product trainingManaged care and payer negotiations

Best For

Brand ManagerMedical Science LiaisonRegional Sales ManagerField Medical RepresentativePayer Relations ManagerRegulatory Specialist

Hiring Landscape

$84K-$314K

The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.

510
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

43Stable
70Growing
45Stable
15Stable

By Department

Commercial(23%)
$122K
Engineering(11%)
$111K
Medical Affairs(3%)
$314K
IT(4%)
$84K
Manufacturing(3%)

Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
1
Lopinavir-RitonavirPhase 3Small Molecule1 trial
Active Trials
NCT04381936Recruiting70,000Est. Sep 2038
AIM ImmunoTech
AIM ImmunoTechFL - Ocala
1 program
1
Alferon LDOPhase 21 trial
Active Trials
NCT00215826Completed10Est. Apr 2006
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Alteplase 50 MG [Activase]Phase 2
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
OtilimabPhase 2Monoclonal Antibody
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
Collection of Convalescent SARS Plasma by ApheresisN/A1 trial
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)N/A1 trial
Active Trials
NCT00342524CompletedEst. Feb 2007
NCT00073086Withdrawn0Est. Dec 2010
CureVac
CureVacGermany - Tübingen
1 program
CVnCoV VaccinePHASE_1Vaccine1 trial
Active Trials
NCT04449276Completed280Est. Dec 2021
Genentech
GenentechCA - Oceanside
1 program
Alteplase 50 MG [Activase]PHASE_21 trial
Active Trials
NCT04357730Completed50Est. Sep 2021
Labcorp
LabcorpBURLINGTON, NC
1 program
Lopinavir-RitonavirPHASE_3Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Innovation PharmaceuticalsLopinavir-Ritonavir
GenentechAlteplase 50 MG [Activase]
AIM ImmunoTechAlferon LDO
CureVacCVnCoV Vaccine
Allergy TherapeuticsCollection of Convalescent SARS Plasma by Apheresis
Allergy TherapeuticsEvaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)

Clinical Trials (6)

Total enrollment: 70,340 patients across 6 trials

Randomised Evaluation of COVID-19 Therapy

Start: Mar 2020Est. completion: Sep 203870,000 patients
Phase 3Recruiting
NCT04357730GenentechAlteplase 50 MG [Activase]

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Start: May 2020Est. completion: Sep 202150 patients
Phase 2Completed

Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers

Start: Nov 2004Est. completion: Apr 200610 patients
Phase 2Completed
NCT04449276CureVacCVnCoV Vaccine

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Start: Jun 2020Est. completion: Dec 2021280 patients
Phase 1Completed
NCT00342524Allergy TherapeuticsCollection of Convalescent SARS Plasma by Apheresis

Collection of Convalescent SARS Plasma by Apheresis

Start: Jul 2005Est. completion: Feb 2007
N/ACompleted
NCT00073086Allergy TherapeuticsEvaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)

Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)

Start: Nov 2003Est. completion: Dec 20100
N/AWithdrawn

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 70,340 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.